Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Entrada Therapeutics stock

Learn how to easily invest in Entrada Therapeutics stock.

Entrada Therapeutics is a biotechnology business based in the US. Entrada Therapeutics shares (TRDA) are listed on the NASDAQ and all prices are listed in US Dollars. Entrada Therapeutics employs 130 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy Entrada Therapeutics stock

  1. Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – TRDA. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Best for low fees

Finder Award

SoFi Invest

  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Best for beginners

Finder Award


  • Easy to use platform with $0 stock trading & no annual fees
  • Social trading allows you to copy popular portfolios
  • FINDER EXCLUSIVE: Guaranteed $15 bonus when you sign up and deposit $100

Promoted for options trading


  • $0 commissions on stocks and ETFs
  • $0 closing commissions on stock and ETF options
  • Get $100 - $2,000 when you open and fund an account with $5,000 to $100,000+

Entrada Therapeutics stock price (NASDAQ: TRDA)

Use our graph to track the performance of TRDA stocks over time.

Entrada Therapeutics shares at a glance

Information last updated 2023-03-24.
Latest market close$14.77
52-week range$5.12 - $24.38
50-day moving average $13.09
200-day moving average $14.12
Wall St. target price$18.00
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-4.08

Buy Entrada Therapeutics stocks from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 6 of 6
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Finder Award
Stocks, Options, ETFs, Cryptocurrency
FINDER EXCLUSIVE: Get a guaranteed $15 bonus
when you sign up and deposit $100
Winner of Finder’s Best Broker for Beginners award. Not available in NY, NV, MN, TN, and HI.
Stocks, Options, ETFs, Cryptocurrency, Futures
Get $100 - $2,000
when you you open and fund an account with $5,000 to $100,000+
Highly commended for Best Derivatives Trading Platform award.
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs, Treasury Bills
Get $50 - $700
when you open and fund an account with $10,000 - $250,000+
Stocks, Bonds, Options, Mutual funds, ETFs, Futures
Get up to $600 or more
when you open and fund a new account.
E*TRADE offers commission-free stocks, access to mutual funds and advanced trading tools. Other fees apply.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Is it a good time to buy Entrada Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Entrada Therapeutics price performance over time

Historical closes compared with the close of $14.77 from 2023-03-29

1 week (2023-03-23) -8.83%
1 month (2023-03-02) 45.52%
3 months (2022-12-30) 9.25%
6 months (2022-09-30) -6.28%
1 year (2022-03-30) 54.66%
2 years (2021-03-26) N/A
3 years (2020-03-26) N/A
5 years (2018-03-26) N/A

Entrada Therapeutics financials

Gross profit TTM $0
Return on assets TTM -21.79%
Return on equity TTM -37.01%
Profit margin 0%
Book value $6.77
Market capitalisation $535.8 million

TTM: trailing 12 months

Entrada Therapeutics share dividends

We're not expecting Entrada Therapeutics to pay a dividend over the next 12 months.

Entrada Therapeutics overview

Entrada Therapeutics, Inc. , a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead therapeutic candidates, which include ENTR-601-44 and ENTR-601-45, which are in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1; ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy; and ENTR-701, which is in preclinical trail for the treatment of myotonic dystrophy type 1. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc.

Frequently asked questions

What percentage of Entrada Therapeutics is owned by insiders or institutions?
Currently 16.139% of Entrada Therapeutics shares are held by insiders and 74.87% by institutions.
How many people work for Entrada Therapeutics?
Latest data suggests 130 work at Entrada Therapeutics.
When does the fiscal year end for Entrada Therapeutics?
Entrada Therapeutics's fiscal year ends in December.
Where is Entrada Therapeutics based?
Entrada Therapeutics's address is: 6 Tide Street, Boston, MA, United States, 02210
What is Entrada Therapeutics's ISIN number?
Entrada Therapeutics's international securities identification number is: US29384C1080

More guides on Finder

Ask an Expert provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site